Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Trip.com Group Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Trip.com Group Ltd trades at $42.79 (market cap $26.45B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Trip.com Group Ltd pays a 0.57% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | TCOM | |
|---|---|---|
Market Cap | $39.89B | $26.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $78.96 |
52-Week Low | $278.09 | $39.84 |
Enterprise Value | $38.15B | $19.15B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Trip.com Group (TCOM) trades at $42.80, up 3.31% on the day, with strong fundamentals including a P/E of 6.43 and net income margin of 48.65%. The stock faces technical headwinds with a bearish signal from moving averages and RSI at 82.74 suggesting overbought conditions. Recent Q1 2026 earnings missed expectations at $0.83 vs. $0.85, while revenue guidance for Q2 2026 of 3%-8% growth disappointed investors, triggering an 18% selloff on June 29, 2026.
Despite near-term pressure from regulatory scrutiny and conservative guidance, Trip.com maintains robust profitability and analyst consensus of $56.72 price target with 67% buy ratings. The company's dominant position in China's travel market and strong cash flow generation provide long-term upside potential, though regulatory risks and margin compression remain key concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
